CMR-based assessment of long-term effects of tafamidis in patients with cardiac transthyretin amyloidosis
Clinical Research in Cardiology · 2026
DOI: 10.1007/s00392-025-02691-8 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Research in Cardiology, 2026. Verfasst von Alexandru Zlibut und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology I, Division of Cardiovascular Imaging, University Hospital Münster, Von-Esmarch-Str. 48, 48149, Münster, Germany. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Cardiomyopathies, Magnetic Resonance Imaging, Cine, Benzoxazoles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Münster.
Abstract (Originalsprache)
Objectives and background The aim of the study was to evaluate the long-term effects of tafamidis on cardiac disease progression beyond 12 months of treatment by performing (among others) serial multi-parametric cardiovascular magnetic resonance (CMR) studies in patients with transthyretin (ATTR) cardiac amyloidosis (CA) cardiomyopathy (ATTR-CM).
Methods
Patients with confirmed ATTR-CM ( N = 56) were divided into two groups: in the larger group A ( N = 39; 95% male), treatment with tafamidis 61 mg once daily was initiated after the first CMR study, whereas group B ( N = 17; 76% male) comprised ATTR-CM patients who did not receive tafamidis. The observational follow-up period lasted 27 ± 6 months. During this period, patients underwent two multi-parametric CMR studies at our institution as part of a routine clinical observation pipeline.
Results
Clinical symptoms assessed by the NYHA class showed a slight, however, significant increase in both groups. NT-proBNP levels substantially increased in both groups at follow-up, however, with a significantly higher increase in the tafamidis-naïve group B ( p = 0.014). LV systolic function, defined by LV-EF and 3D global longitudinal peak strain, significantly worsened in both groups at follow-up (54% to 48% p < 0.001 vs 56% to 46%, p < 0.001; −7.4 to −5.3, p < 0.001 vs −8.8 to −4.8, p < 0.001). However, the tafamidis-naïve group B experienced a substantially higher impairment of both parameters when compared to group A (∆p = 0.008 and ∆p = 0.003, respectively). LV wall thickness considerably increased in both groups at follow-up, however, with a significantly higher increase in the tafamidis-naïve group B (from 18.2 mm to 21.1 mm at follow-up, p < 0.001) compared to the tafamidis-treated group A (from 18.5 mm to 19.2 mm, p = 0.012; ∆ p < 0.001). Both global native T1 and global ECV values were significantly elevated in both groups—at baseline and at follow-up—with a significant increase in both groups during follow-up. However, a substantially higher increase in global ECV was observed in the tafamidis-naïve group B compared to the tafamidis-treated group A (group A: 51% to 57%, p < 0.001; group B: 50% to 67%, p < 0.001; ∆p < 0.001).
Conclusion
Substantial worsening of clinical symptoms, serum biomarkers, and imaging parameters occurred in both tafamidis-treated and tafamidis-naïve ATTR-CM patients within a follow-up period of approximately 2 years. However, the “extent of worsening” is significantly lower in the tafamidis-treated compared to the tafamidis-naïve patients. Graphical abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology I, Division of Cardiovascular Imaging, University Hospital Münster, Von-Esmarch-Str. 48, 48149, Münster, Germany.
- Department of Cardiology I, Division of Cardiovascular Imaging, University Hospital Münster, Von-Esmarch-Str. 48, 48149, Münster, Germany. Ali.Yilmaz@ukmuenster.de.
Förderung
- Universitätsklinikum Münster
Zitieren
APA
Zlibut, A., Bietenbeck, M., Akyol, N., Vehof, V., Bouras, R., Isgandarova, K., Meier, C., Theofanidou, M., Stalling, P., & Yilmaz, A. (2026). CMR-based assessment of long-term effects of tafamidis in patients with cardiac transthyretin amyloidosis. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-025-02691-8
Vancouver
Zlibut A, Bietenbeck M, Akyol N, Vehof V, Bouras R, Isgandarova K, et al. CMR-based assessment of long-term effects of tafamidis in patients with cardiac transthyretin amyloidosis. Clinical Research in Cardiology. 2026. doi:10.1007/s00392-025-02691-8
BibTeX
@article{Zlibut2026,
author = {Zlibut, Alexandru and Bietenbeck, Michael and Akyol, Nuriye and Vehof, Volker and Bouras, Redouane and Isgandarova, Khuraman and Meier, Claudia and Theofanidou, Maria and Stalling, Philipp and Yilmaz, Ali},
title = {CMR-based assessment of long-term effects of tafamidis in patients with cardiac transthyretin amyloidosis},
journal = {Clinical Research in Cardiology},
year = {2026},
doi = {10.1007/s00392-025-02691-8}
}
EUVIMED